Celcuity (CELC) Q3 2026 Earnings Call Transcript

Celcuity (CELC) reported strong Q3 2026 results, with Revtopik, its drug for advanced breast cancer, showing high adoption. 78% of top accounts ordered it, and 91% of U.S. commercial and Medicare lives have coverage. The company estimates a $9B annual market. Clinical data showed significant efficacy, and Celcuity plans to submit data to global regulators.

Original reporting

finance.yahoo.com

Published Nov 6, 2026, 5:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 6, 2026, 5:25 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Celcuity (CELC) Q3 2026 Earnings Call Transcript — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$CELCBullishHigh

Why it matters

The disclosed metrics and trial outcomes provide fresh, material information likely to move the stock.

Market read

First report of commercial uptake and positive trial data; high relevance for traders focused on biotech catalysts.

What to watch

Potential reimbursement challenges and competition from other PI3K inhibitors could limit upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Celcuity announced commercial availability of Revtopik and presented late‑breaking ESMO data showing superior progression‑free survival versus alpelisib.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CELCBullishHigh confidence

Context

Transcript reveals commercial launch metrics for Revtopik and positive Phase 2/3 trial results presented at ESMO, indicating strong efficacy and safety.

Expected impact

likely upward pressure as investors price in strong efficacy and expanding market access

Evidence & confidence

New efficacy numbers, NCCN guideline inclusion, and high payer coverage signal revenue growth potential.

Market effects

Sector

Boosts sentiment for the oncology biotech sector and PI3K pathway therapeutics.

Regional

Positive for US biotech equities, especially small‑cap cancer drug developers.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

If trial data does not translate to real‑world sales, the hype could fade and the stock may correct.

Key entities

company
Celcuity
US‑listed biotech developing the PI3K inhibitor gedatolisib (Revtopik).

Read at source ← All news

$CELCLowAI 8/10

FDA Accepts Celcuity's REVTORPYK Application; Decision Expected In June 2027; Stock Up

Celcuity Inc. (CELC) announced the FDA accepted its sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2-negative, PIK3CA-mutated advanced breast cancer. A decision is expected by June 25, 2027. The drug targets the PI3K/AKT/mTOR pathway and is supported by Phase 3 trial data. CELC stock rose 5.17% to $70.24.

rttnews.comNov 9

$CELCHighAI 8/10

FDA accepts Celcuity application for expanded breast cancer use

Celcuity Inc. (CELC) announced the FDA accepted its application to expand the use of REVTORPYK for treating specific breast cancer patients. The FDA set a review goal date of June 25, 2027, based on Phase 3 trial data. The drug is already approved for a similar indication without PIK3CA mutations. Celcuity is developing REVTORPYK for other cancer treatments.

investing.comNov 9

$CELCLowAI 8/10

Celcuity Inc. (CELC) FDA Sets June 25, 2027 Review Goal for sNDA

Celcuity Inc. (CELC) announced the FDA accepted its supplemental New Drug Application (sNDA) for REVTORPYK, aiming to treat a specific type of breast cancer. The FDA set a goal date of June 25, 2027, for review. This follows the drug's expected approval in July 2026 for patients without a detected PIK3CA mutation.

tradingview.comNov 9

$CELCMedAI 8/10

What Celcuity (CELC) Said on Its Q3 Earnings Call

Celcuity (CELC) reported Q3 earnings, highlighting sufficient production capacity and regulatory updates. The company submitted a supplemental new drug application to the FDA and expects to provide further data to global regulators. Operating expenses rose to $77.3M, driven by commercial spending. Celcuity ended the quarter with $642.7M in cash and expects it to fund operations through 2029.

finance.yahoo.comNov 6

$CELCLow

Celcuity 3Q 2026: Revenue $0, EPS ($1.33) — 10-Q Summary

Celcuity reported no revenue in Q3 2026, with a net loss of $73.34M and EPS of ($1.33). Expenses rose due to commercialization efforts. REVTORPYK launched commercially, and the company submitted an sNDA for its use in advanced breast cancer. New data was presented at ESMO Congress, and a prostate cancer study showed promising results.

tradingview.comNov 5

$CELCHighAI 9/10

Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Celcuity Inc. (CELC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVTORPYK became commercially available on September 30th for the treatment of patients with HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancer 91% of U.S. c

SEC EDGAR 8-KNov 5